Advertisement
A live audio webcast of the presentation will be available under theinvestor relations section of Arena's website at http://www.arenapharm.com. Areplay of the presentation will be available for at least 30 days followingthe event. Please connect to Arena's website several minutes prior to thestart of the webcast to ensure adequate time for any software download thatmay be necessary.
Advertisement
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused ondiscovering, developing and commercializing oral drugs in four majortherapeutic areas: cardiovascular, central nervous system, inflammatory andmetabolic diseases. Arena's most advanced drug candidate, lorcaserin, is beinginvestigated in a Phase 3 clinical trial program for the treatment of obesity.Arena's broad pipeline of novel compounds target G protein-coupled receptors,an important class of validated drug targets, and includes compounds beingevaluated independently and with partners, including Merck & Co., Inc. andOrtho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals(R) and Arena(R) are registered service marks of thecompany. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Forward-Looking Statements
Certain statements in this press release are forward-looking statementsthat involve a number of risks and uncertainties. Such forward-lookingstatements include statements about Arena's strategy, internal and partneredprograms, and ability to develop compounds and commercialize drugs. For suchstatements, Arena claims the protection of the Private Securities LitigationReform Act of 1995. Actual events or results may differ materially fromArena's expectations. Factors that could cause actual results to differmaterially from the forward-looking statements include, but are not limitedto, clinical trials and studies may not proceed at the time or in the mannerArena expects or at all, the results of clinical trials or preclinical studiesmay not be predictive of future results, Arena's ability to receive regulatoryapproval for its drug candidates, Arena's ability to partner lorcaserin,APD125, APD791 or other of its compounds or programs, the timing, success andcost of Arena's research, out-licensing endeavors and clinical trials, Arena'sability to obtain additional financing, Arena's ability to obtain and defendits patents and the timing and receipt of payments and fees, if any, fromArena's collaborators. Additional factors that could cause actual results todiffer materially from those stated or implied by Arena's forward-lookingstatements are disclosed in Arena's filings with the Securities and ExchangeCommission. These forward-looking statements represent Arena's judgment as ofthe time of this release. Arena disclaims any intent or obligation to updatethese forward-looking statements, other than as may be required underapplicable law.Contacts: Jack Lief Mary Claire Duch President and CEO WeissComm Partners Media Relations David Walsey 212.301.7228 Director, Corporate Communications Arena Pharmaceuticals, Inc. 858.453.7200, ext. 1682 http://www.arenapharm.com
SOURCE Arena Pharmaceuticals, Inc.
